Detailed answers about TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C., including incorporation, status, business activity, and accounts information.
When was TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. founded?
TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. was officially incorporated on 24 June 2023 and is registered under company number 14959189. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C.?
Community Interest Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations.
What is the current status of TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C.?
TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C.'s current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. do?
TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. operates in the following sector: 86900 - Other human health activities. This provides insight into the company's primary business activity and industry focus.
What is TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C.'s registered address?
The registered office address of TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. is 2 HOLLY HEDGE ROAD, FRIMLEY, CAMBERLEY, ENGLAND, GU16 8SU. This is the official address filed with Companies House for legal and statutory correspondence.
Is TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. financially stable?
The most recent accounts for TASMIA-ASIF CANCER HOSPITAL & RESEARCH CENTRE C.I.C. were made up to 31 July 2024, filed as TOTAL EXEMPTION FULL. Next accounts are due by 30 April 2026.